Treating Venous Thromboembolism Post Intracranial Hemorrhage: A Case Report

被引:3
作者
Ajmeri, Aman N. [1 ]
Zaheer, Kamran [1 ]
McCorkle, Colin [1 ]
Amro, Ahmed [2 ]
Mustafa, Bisher [1 ]
机构
[1] Marshall Univ, Joan C Edwards Sch Med, Internal Med, Huntington, WV 25755 USA
[2] Marshall Univ, Joan C Edwards Sch Med, Cardiol, Huntington, WV USA
关键词
factor v leiden; ich; anticoagulation; ivc filter; pe; cerebral cavernous malformation; ccm-related bleeding; cavernous angioma; intracranial hemorrhage; pulmonary embolism; ACTIVATED PROTEIN-C; FACTOR-V; INTRACEREBRAL HEMORRHAGE; ANTITHROMBOTIC THERAPY; THROMBOSIS; WARFARIN; RISK; MUTATION; STROKE;
D O I
10.7759/cureus.6746
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Venous thromboembolism (VTE) is a significant issue occurring due to genetic, acquired and circumstantial risk factors. Treatment is according to the clinical situation and judgment for long term anticoagulation based on individual risk. Anticoagulation after a history of a hemorrhagic stroke poses a therapeutic dilemma. We present a case of a 68-year-old male who presented with right-sided chest pain and shortness of breath. Workup included a CT that was positive for multiple right-sided pulmonary emboli (PE). The patient has a past medical history of Factor V Leiden Mutation, recurrent PE, and deep vein thrombosis (DVT). Two months prior he was diagnosed with a 1.3-cm intracranial hemorrhage (ICH) from multiple cavernous angiomas. At that time his warfarin was discontinued and an inferior vena cave (IVC) filter was placed. Facing the recent ICH and now multiple and recurrent PE, it was decided to resume anticoagulation based on ICH location. ICH from a deep source is likely a better characteristic that favors a resumption of anticoagulation. Our case will highlight that IVC filters cannot be solely relied upon in patients that are at high risk for thrombotic events with underlying genetic thrombophilia.
引用
收藏
页数:12
相关论文
共 20 条
[1]  
Albagoush SA, 2019, FACTOR V LEIDEN DEFI
[2]  
[Anonymous], FACTOR V LEIDEN THRO
[3]   Risk of recurrent venous thromboembolism in patients with the factor V Leiden (FVR506Q) mutation: effect of warfarin and prediction by precipitating factors [J].
Baglin, C ;
Brown, K ;
Luddington, R ;
Baglin, T .
BRITISH JOURNAL OF HAEMATOLOGY, 1998, 100 (04) :764-768
[4]   Vena Cava Filter Use in Trauma and Rates of Pulmonary Embolism, 2003-2015 [J].
Cook, Alan D. ;
Gross, Brian W. ;
Osler, Turner M. ;
Rittenhouse, Katelyn J. ;
Bradburn, Eric H. ;
Shackford, Steven R. ;
Rogers, Frederick B. .
JAMA SURGERY, 2017, 152 (08) :724-732
[5]  
DESTEFANO V, 1995, HAEMATOLOGICA, V80, P344
[6]   Can patients be anticoagulated after intracerebral hemorrhage? A decision analysis [J].
Eckman, MH ;
Rosand, J ;
Knudsen, KA ;
Singer, DE ;
Greenberg, SM .
STROKE, 2003, 34 (07) :1710-1716
[7]   Death and disability from warfarin-associated intracranial and extracranial hemorrhages [J].
Fang, Margaret C. ;
Go, Alan S. ;
Chang, Yuchiao ;
Hylek, Elaine M. ;
Henault, Lori E. ;
Jensvold, Nancy G. ;
Singer, Daniel E. .
AMERICAN JOURNAL OF MEDICINE, 2007, 120 (08) :700-705
[8]   Use of antithrombotic agents in patients with intracerebral cavernous malformations [J].
Flemming, Kelly D. ;
Link, Michael J. ;
Christianson, Teresa J. H. ;
Brown, Robert D., Jr. .
JOURNAL OF NEUROSURGERY, 2013, 118 (01) :43-46
[9]   Atrial fibrillation patients who sustained warfarin-associated intracerebral haemorrhage have poor neurological outcomes: results from a matched case series [J].
Fong, M. K. ;
Sheng, B. ;
Chu, Y. P. ;
Wong, W. T. ;
Lau, Patrick P. K. ;
Wong, H. Y. ;
Lau, K. K. .
HONG KONG MEDICAL JOURNAL, 2017, 23 (02) :117-121
[10]   Should anticoagulation be resumed after intracerebral hemorrhage? [J].
Goldstein, Joshua N. ;
Greenberg, Steven M. .
CLEVELAND CLINIC JOURNAL OF MEDICINE, 2010, 77 (11) :791-799